论文部分内容阅读
Olaratumab是一种重组人源免疫球蛋白G1(IgG1)单克隆抗体,可特异性结合并阻断血小板衍生生长因子受体α(PDGFRα),抑制PDGFRα促进肿瘤和基质细胞(包括肉瘤)增殖、转移并维持肿瘤微环境的作用.2016-10-19,美国食品药品监督管理局(FDA)批准olaratumab联合多柔比星用于不适合根治性放射治疗或手术、但适合蒽环类治疗的成人晚期软组织肉瘤(STS)组织学亚型,是首个被批准用于治疗STS的单克隆抗体.本文对olaratumab的作用机制、药代动力学、临床应用和安全性方面做一综述.“,”Olaratumab,a recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal blocking antibody that binds specifically to human platelet-derived growth factor receptor alpha (PDGFRα),plays an important role in inhibition of PDGFRα-induced cancer cell proliferation,metastasis,and maintenance of the tumor microenvironment.On October 19th,2016 Food and Drug Adminstration (FDA) approved olaratumab as the flrst monoclonal antibody,in combination with doxorubicin,for the treatment of adult patients with soft tissue sarcoma (STS)with a histologic subtype which can be treated by anthracycline-containing regimen without radiotherapy or surgery.In this article,the mechanism,pharmacokinetics,clinical application and adverse reactions of olaratumab were reviewed.